Universe Pharmaceuticals (UPC) Receivables (2020 - 2025)
Universe Pharmaceuticals (UPC) has disclosed Receivables for 6 consecutive years, with $15.3 billion as the latest value for Q3 2025.
- Quarterly Receivables rose 114.58% to $15.3 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $15.3 billion through Sep 2025, up 114.58% year-over-year, with the annual reading at $15.3 billion for FY2025, 114.58% up from the prior year.
- Receivables hit $15.3 billion in Q3 2025 for Universe Pharmaceuticals, up from $7.1 billion in the prior quarter.
- In the past five years, Receivables ranged from a high of $15.3 billion in Q3 2025 to a low of $12.9 million in Q3 2023.
- Historically, Receivables has averaged $4.5 billion across 5 years, with a median of $16.3 million in 2021.
- Biggest five-year swings in Receivables: fell 14.81% in 2023 and later skyrocketed 54982.0% in 2024.
- Year by year, Receivables stood at $16.3 million in 2021, then decreased by 6.6% to $15.2 million in 2022, then fell by 14.81% to $12.9 million in 2023, then surged by 54982.0% to $7.1 billion in 2024, then skyrocketed by 114.58% to $15.3 billion in 2025.
- Business Quant data shows Receivables for UPC at $15.3 billion in Q3 2025, $7.1 billion in Q3 2024, and $12.9 million in Q3 2023.